Dengue Vaccine India: The first dengue vaccine in India gets the green signal, know who will get this dose and how?

Dengue Symptoms and Treatment: The country has received its first dengue vaccine. This step is considered a major step towards prevention, not just treatment. Let's explain it.

 

 

What is the Dengue Vaccine In India? The threat of dengue in India is increasing every year, especially during the monsoon season when hospitalizations surge. In such a situation, news of significant relief has emerged: the country has received its first dengue vaccine. This step is being considered a major step towards prevention, not just treatment. Let us explain how this is a significant relief for the country.

Dengue-related cases

According to government data, dengue cases have steadily increased over the past few years. While around 44,000 cases were reported in 2020, this number exceeded 230,000 in 2023 and 2024. In 2025, more than 113,000 cases have been reported as of November. Experts believe the actual figure could be even higher, as many cases go unreported.

Vaccine approval

Now, the TAK-003 vaccine, known as Qdenga, has been approved in India. An expert committee under the Drug Controller General of India has approved its use for people aged 4 to 60. This vaccine was developed by Takeda Pharmaceutical Co., Ltd. of Japan. The unique feature of this vaccine is that it does not affect the risk of previous dengue fever. This was a major challenge with previous vaccines. Qdenga is designed to protect against all four dengue virus serotypes, providing more comprehensive protection.

How does it work?

It is given in two doses, three months apart. Clinical trials have shown that this vaccine can provide protection for more than four years. The World Health Organization has also considered it useful in areas where the risk of dengue is high. Dr. Archana Pate told TOI that India accounts for approximately one-third of the world's population at risk of dengue. Therefore, this vaccine could prove to be an important step for public health.

However, experts also agree that this is not a magic solution. The vaccine will certainly reduce the risk of dengue, but it cannot completely eliminate it. The severity of dengue often depends on the body's immune response, especially after a second infection. Another piece of good news is that this vaccine will be produced in India. Takeda has partnered with Hyderabad-based Biological E. Limited, which may improve both its availability and cost in the future. Doctors are clear that the vaccine alone will not suffice. Preventing mosquito breeding, maintaining cleanliness, timely testing, and proper treatment are all equally important.